Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism

Definitions

• the present invention relates to new pyrazolo[l ,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators.
• the invention also relates to the process for producing such compounds.
• the invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism.
• the invention also provides a method for manufacture of medicaments useful in the treatment of such disorders.
• GABA Gamma-aminobutyric acid
• GABA is the main inhibitory neurotransmitter in the central nervous system and plays a key role in modulating neuronal activity. It exerts its action via three receptor systems, the related ionotropic GABAA and GAB Ac receptors, and the distinct metabotropic GABAB receptors (Hill and Bowery, Nature 1981, 290, 149- 152).
• the latter GABAB receptors are widespreadly distributed within the mammalian central nervous system with various expression levels in different brain regions (Bovery et al, Neuroscience 1987, 20, 365-385). GABAB receptors can be found both pre- and postsynaptically and play an important role in the fine-tuning of neurotransmission.
• GABAB receptors cluster around excitatory synapses, either at the edge of the presynaptic terminal or on dendritic spines opposite to glutamatergic boutons (Ulrich and Bettler, Curr. Opin. NeurohioL 2007, 17, 298- 303).
• GABAB receptors belong to the Family 3 (C) of G-protein coupled receptors (GPCRs) together with metabotropic glutamate receptors (mGluRs), calcium-sensing receptors, taste receptors and a number of orphan receptors, showing highest, approximately 30% homology to mGluRs (Bettler et ai, Physiol Rev. 2004, 84, 835-867).
• GABAB receptors are heterodimers consisting of two similar, yet different subunits, Bl and B2. The Bl subunit has multiple splice variants with only two (Bla and B ib) having clear physiological significance.
• the Bl subunit binds the endogenous neurotransmitter ligand GABA as well as other orthosteric agonists (such as baclofen, SKF97541) and antagonists (such as phaclofen, saclofen).
• the B2 subunit is responsible for G-protein activation-mediated intracellular signal transduction and is believed to bind allosteric modulators (Binet et al, J. Biol.
• the site of action for the Novartis GABAp, positive allosteric modulator compounds CGP7930 and GS39783 is the heptahelical transmembrane domain of the B2 subunit; the exact binding site for other, unrelated positive allosteric modulator chemotypes is not known.
• GABAB receptors The main synaptic effects of GABAB receptors are the presynaptic blockade of neurotransmitter release (GABA as well as giutamate) and postsynaptic hyperpolarization (Gassmann and Bettler, in Handbook of Contemporary Neuropharmacology 2007). These effects are the result of inhibition of presynaptic calcium influx and stimulation of postsynaptic inwardly rectifying potassium (GIRK) channels, respectively. Ion channel functions are mediated in a membrane-delimited manner through the activation of ⁇ subunits of Gi/G 0 proteins.
• GABAB receptors also signal via the a subunit of the same G- proteins that inhibits adenylate cyclase and retards the recruitment of synaptic vesicles (Chalifoux and Carter, Curr. Opin. Neurobiol. 201 , 21 , 339-442). Beside these fast cellular events, GABAB receptors also regulate cytoplasmic kinases including mitogen-aeivated protein kinase and thereby influence synaptic plasticity on the longer-term.
• mice have been generated with mutations selectively in the Bl, Bla, B i b and the B2 subunits.
• Mice without Bl subunits displayed increased anxiety in explorative- like situations (light-dark box, staircase assays), increased panic, spontaneous seizures, hyperalgesia, hyperlocomotion, and memory impairment (Schuler et al. Neuron 2001 , 31, 47- 58).
• Mice that do not express GABAB2 subunits behave similarly to Bl subunit knockouts; these animals are overanxious, show spontaneous seizure activity, hyperalgesia, hyperlocomotion, and memory impairment (Mombereau et al, Eur. J. Pharmacol.
• baclofen may have potential therapeutic benefits in treating conditions including asthma, pain, obesity, binge eating, drag and alcohol abuse, anxiety, posttraumatic stress disorder, cough, inflammation, gastroeasophageal reflux and urinary incontinence (eg., Breslow et al, Am. J. Psychiatry 1989, 146, 353-356; Drake et al, Ann. Pharmacother. 2003, 37, 1177-1 81; Leggio et al, CNS Neurol.
• baclofen has beneficial potential in a number of therapeutic indications, unfortunately it also has a range of unwanted properties including poor blood-brain- barrier penetration, narrow therapeutic window, receptor desensitization, development of tolerance against the main effects, and withdrawal upon termination of use (Vacher and Bettler, Citrr. Drug Targets CNS Neurol Disord. 2003, 2, 248-259; Ross et al, Neurocrit. Care 2011, 14, 103-108, Keegan et al, Neuropharmacology 2015, 95, 492-502).
• Allosteric modulation is an alternative way to selectively stimulate GPCRs without the unwanted properties of orthosteric ligands (Conn et al, Nat Rev 2009, 8, 41-54, Wang et al, J. Pharmacol. Exp. Ther. 2009, 331 , 340-348). Allosteric modulators bind to the receptors at sites that are different from the binding site of the endogenous (orthosteric) ligands and are effective predominantly if an agonist is also bound to the receptor. This has consequences on the temporal and spatial pattern of efficacy which in turn affects the behavioral and adaptive responses the organism gives to allosteric stimulation.
• a representative positive ailosteric compound (2- ⁇ l-[2-(4-chlorophenyl)-5- methylpyrazolo[l,5-a]pyrimidin-7-yl]-2-piperidinyl ⁇ ethanol, CMPPE) belonging to a novel chemotype has been reported by Perdona and co-workers (Perdona et al, Neuropharmacology 201 1 , 61 , 957-966), CMPPE positively modulated the EC20 GABA-evoked in vitro [ 35 S]GTPyS binding signal with an EC so value of 2.57 ⁇ (in our in vitro [ 35 S]GTPyS test system CMPPE showed an EC so value of 61 1 nM ).
• CMPPE In Perdona et al, the compound showed mild efficacy in a food consumption test in rats reaching significance only at high doses (30 and 100 mg/kg).
• CMPPE In a functional in vivo assay (potentiation of bacl of en-induced muscle relaxation in mice) CMPPE showed weak activity with an ED 50 value of 53.8 mg/kg. Modest in vitro activity of CMPPE translates into weak in vivo activity.
• the compound has poor metabolic stability in liver microsomal systems (Clint 0.19 ⁇ 0.02, 0.3 1 ⁇ 0.07, 1. 18 ⁇ 0.4 mL/min/g liver in human, rat and mouse conventional liver microsomes, respectively).
• CMPPE is a singleton and represents a chemotype that needs extensive optimization before it could be utilized to treat human diseases or disorders associated with the GABAB receptor system.
• the present invention relates to compounds being GABAB receptor positive allosteric modulators and the synthesis thereof. Compounds of the present invention are useful for the treatment of the above disorders.
• the present invention relates to the pyrazolo[l,5-a]pyrimidine derivatives of formula
• A is an optionally substituted phenyl or pyridyl group
• B is hydrogen or halogen atom, methyl, cyano group
• C is Ci-&alkyl
• Ci-ealkyl optionally substituted by a halogen atom or halogen atoms, C 3-5 cycloalkyl; C-j-scycioalkylC i-ealkyl, dialkylamino, Ci-ealkoxyC i-ealkyl, Ci-ealkylthio group, tetrahydrofuranyl, tetrahydrofuranylCi-ealkyl, tetrahydropyranyl, tetrahydropyranylC i-eaikyl; or C and D together form an unsubstituted or substituted by one or more Ci-saikyl, Ci- alkoxy, haloC i-3alkyl, d alkylcarbonyl 3 to 7-membered saturated ring, wherein the members of the ring are selected from the group consisting of carbon, nitrogen, oxygen, and sulphur;
• R 1 is hydrogen, halogen atom or C i-ealkyl, hydroxyl, Ci-ealkoxy, C i-ealkoxyCi-eafkyl, halod- &alkyl, amino group; or pharmaceutically acceptable salts, biologically active metabolites, prodrugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof.
• the invention also relates to the pharmaceutical compositions containing the compounds of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof as active ingredient.
• the present invention relates to the synthesis of the compounds of formula (I) and optical antipodes or racemates and/or salts thereof, the pharmaceutical compositions comprising thereof and the manufacture of medicaments containing these compounds, as well as the methods of treatment with these compounds, which means administering to a mammal to be treated - including human - suffering from disorders psychiatric, neurodevelopmental, neurological and other central nervous system disorders as well as peripheral conditions where modulation of the GABAB receptor might have therapeutic benefit, effective amount of compounds of formula (I) and optical antipodes or racemates and/or salts thereof of the present invention as such or as medicament.
• the present invention relates to pyrazolo[l,5-a]pyrimidine derivatives of formula (I)
• A is an optionally substituted phenyl or pyridyl group
• B is hydrogen or halogen atom, methyl, cyano group
• C is C 1 .6 alkyl
• D is d -6 alkyl optionally substituted by a halogen atom or halogen atoms, C3-5 cycloalkyl; C3-5 cycloalkylC i-ealkyl, dialkylamino, Ci-ealkoxy, C i-ealkoxyd-eaikyl, d-ealkylthio group, tetrahydrofuranyl, tetrahydrofuranylC l-ealkyl, tetrahydropyranyl, tetrahydropyranylC i -6 alkyl; or C and D together form an unsubstituted or substituted by one or more d-3alkyl, d-salkoxy, haloC 1-3 alkyl, d-3 alkyl carbonyl 3 to 7-membered saturated ring, wherein the members of the ring are selected from the group consisting of carbon, nitrogen, oxygen, and sulphur,
• R l is hydrogen, halogen atom or Ci-ealkyl, hydroxyl, d-ealkoxy, Ci-ealkoxyCi-eaikyl, haloCi- ealkyl, amino group,
• A is an optionally substituted phenyl group
• optionally substituted means that it may be substituted by one, two or three substituent selected from halogen atom, d-Ce-alkoxy group, d-Ce-alkyl, -CN or -CF3 group.
• optionally substituted pyridyl group When the meaning of A is optionally substituted pyridyl group the term "optionally substituted” means that it may be substituted by one or two substituent selected from halogen atom, d-Ce-alkyl, -CN or -CF3 group.
• halogen or "halo” as used herein alone or as a part of another group refers to chlorine, bromine, fluorine and iodine.
• Ci-Ce alkyl refers to branched or straight chain alkyl groups comprising one to sixcarbon atoms, including methyl, ethyl, propyl, normal- and isopropyl and different butyl groups.
• C 3 -C 5 cycloalkyl refers to carbocyclic groups of 3 to 5 carbons, respectively; for example, cyclopropyl, cyclobutyl, and cyclopentyl.
• C i-Ce alkoxy refers to branched or straight chain alkyl groups comprising one to six carbon atoms bonded through an oxygen atom, including but not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, and t-butoxy.
• Ci-ealkylthio refers to branched or straight chain aikyi groups comprising one to six carbon atoms bonded through a sulfur atom, including but not limited to, methyithio, ethylthio, n-propylthio, i-propylthio, and t-butylthio.
• mammal refers to any members of the class “Mammalia” including, but not limited to human.
• salt means nontoxic base addition salts of the compounds of the invention which are generally prepared by reacting the acid with a suitable organic or inorganic base.
• pharmaceutically acceptable describes an ingredient that is useful in preparing a pharmaceutical composition and is generally safe, non-toxic and neither biologically nor othemise undesirable, and includes those acceptable for veterinary use as well as human pharmaceutical use.
• pharmaceutical composition refers to a mixture of a compound of the invention with other chemical components, such as pharmaceutically acceptable excipients e.g. diluents or carriers.
• the pharmaceutical composition facilitates administration of the compound to the subject.
• excipient defines a chemical compound that facilitates the incorporation of a compound into cells or tissues.
• treatment means using an effective therapy to reduce, alleviate or eliminate the symptoms associated with diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism.
• treatment means using an effective therapy to reduce, alleviate or eliminate the symptoms associated with diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism.
• acylacetonitrile derivative (V) can be carried out by different routes: a) The reaction of a carboxylic acid ester derivative of formula (II) with an acetonitrile derivative of formula (IV) is preferably carried out in a suitable solvent, e.g. acetonitrile, preferably in the presence of a strong base e.g. sodium methyl ate. The reaction is preferably carried out at boiling point of the solvent. The necessary reaction time is 1-6 h. The reactions are followed by thin layer chromatography. The reaction is quenched by addition of water, acidified with hydrochloric acid ( pi f 2-3). The product is isolated by filtration or extraction with a suitable organic solvent.
• a suitable solvent e.g. acetonitrile
• a strong base e.g. sodium methyl ate
• the reaction is preferably carried out at boiling point of the solvent.
• the necessary reaction time is 1-6 h.
• the reactions are followed by thin layer chromatography.
• the reaction is que
• the cyciocondensation reaction of the acyl nitrile derivatives of formula (V) with hydrazine hydrate to pyrazole derivatives of formula (VI) is preferably carri ed out in a suitable solvent, e.g. ethanol.
• the reaction is preferably carried out at boiling point of the solvent.
• the necessary reaction time is 1-6 h.
• the reactions are followed by thin layer chromatography.
• the work-up of the reaction mixture can be carried out by the following methods:
• reaction mixture is diluted with water and the product i s isolated by filtration or extraction with a suitable organic solvent and in given case purified by crystallization or column chromatography.
• the cyclocondensation reaction of the lH-pyrazol-5-amine derivative of formula (VI) with an acetoacetic ester derivative of formula (VII) is preferably carried out in a suitable solvent, e.g. toluene, by the addition of catalytic amount of p-toluenesulfonic acid, using a Dean- Stark water separator.
• the reaction is preferably carried out at boiling point of the solvent.
• the necessary reaction time is 1-16 h.
• the reactions are followed by thin layer chromatography.
• the product is isolated by filtration.
• Chlorination of the pyrazolo[l,5-a]pyrimidine derivative of formula (VIII) can be carried out in a suitablesolvent, e.g. toluene using a proper chlorinating agent, e.g. phosphorus oxychloride by the addition of tri ethyl amine or N,N-diisopropylethylamine.
• a suitablesolvent e.g. toluene
• a proper chlorinating agent e.g. phosphorus oxychloride
• the reaction is preferably carried out at boiling point of the solvent.
• the necessary reaction time is 24-48 h.
• the reactions are followed by thin layer chromatography.
• the reaction mixture is poured into sodium hydrogen carbonate solution and chrushed ice.
• the decomposed reaction mixture is filtered and the product is isolated from the filtrate by extraction with a suitable organic solvent and in optionally purified by crystallization or column chromatography.
• the column chromatography is carried out on normal phase using Kieselgel 60 as adsorbent and different solvent systems, e.g. n-hexane/ethyl acetate, toiuene/methanol, chioroform/methanoi or toluene/acetone, as eluents.
• N-arylation reaction of the nipecotic acid derivative of formula (X) or (XII) with the chloro derivative of formula (IX) carried out in a suitable solvent, e.g. dimethylformamide, dimethylsulfoxide, N-methyl-pyrrolidine.
• a suitable solvent e.g. dimethylformamide, dimethylsulfoxide, N-methyl-pyrrolidine.
• the reaction is preferably carried out between 80°C and 140 °C, A suitable amine of formula (X) or (XII) is added as base or as a salt formed with inorganic acid to the so obtained solution in the presence of a base, for example cesium carbonate or ⁇ , ⁇ -diisopropylethylamine, needed for the liberation of the amine or a salt of nipecotic acid derivative of formula (XI) formed with inorganic base, for example potassium salt is used in the reaction.
• a base for example cesium carbonate or ⁇ , ⁇ -diisopropylethylamine
• a salt of nipecotic acid derivative of formula (XI) formed with inorganic base for example potassium salt is used in the reaction.
• the reactions are followed by thin layer chromatography.
• the necessary reaction time is 3-20 h.
• the work-up of the reaction mixture can be carried out by different methods.
• the N-arylated product is an acid derivative of formula (I) and the reaction mixture is a suspension
• the inorganic salt is filtered off, the filtrate is diluted with water and acidified with acetic acid.
• the product is isolated by filtration or extraction with a proper organic solvent and in given case purified by crystallization or column chromatography. If the reaction mixture is a solution, it is diluted with water and acidified with acetic acid.
• the product is isolated by filtration or extraction with a proper organic solvent and in given case purified by crystallization or column chromatography.
• the reaction mixture is evaporated in vacuo.
• the product is isolated by crystallization or extraction with a proper organic solvent and in given case purified by recrystallization or column chromatography.
• the hydrolysis of the carboxylic acid ester derivative of formula (XIII) into the carboxylic acid derivative of formula (I) can be carried out with an appropriate strong inorganic base, e.g. lithium hydroxide, sodium hydroxide or with an appropriate strong inorganic acid, e.g. hydrochloric acid.
• the reaction is preferably carried out between room temperature and 100 °C.
• the reactions are followed by thin layer chromatography.
• the necessary reaction time is 1 -20 h.
• the reaction mixture is diluted with water and acidified with acetic acid.
• the product is isolated by filtration or extraction with a proper organic solvent and in given case purified by crystallization or column chromatography.
• the structures of the products are determined by NMR and mass spectrometry.
• nipecotic acid derivatives of formula (X) and (XII) are either commercially available or can be synthesized by different known methods.
• the syntheses of some new nipecotic acid derivatives of formula (XII) are described in the Intermediate section.
• the compounds of the present invention and optical antipodes or racemates and/or salts thereof can be used as such or suitably in the form of pharmaceutical compositions.
• the invention also relates to the pharmaceutical compositions containing the compounds of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof for the treatment of certain disorders associated with GABAB receptor positive allosteric modulator activity.
• the present compounds may be coadminstered to a subject in combination with two or more different therapeutic agents (eg. most preferably antipsychotics and psychostimulants; and preferably antidepressants, anxiolytics, antihypertensives, anticonvulsants, sedatives, and narcotics).
• two or more different therapeutic agents eg. most preferably antipsychotics and psychostimulants; and preferably antidepressants, anxiolytics, antihypertensives, anticonvulsants, sedatives, and narcotics.
• Suitable routes of administration may, for example, include oral, rectal, transmucosal, transdermal or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intraarticular, intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections and eye drops.
• compositions can be administered through a variety of routes and dosages forms.
• the compound of the invention may be administered either alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses.
• the dosage required to exert the therapeutical effect can vary within wide limits and will be fitted to the individual requirements in each of the particular case, depending on the stage of the disease, the condition and the body weight of the patient to be treated, as well as the sensitivity of the patient against the active ingredient, route of administration and number of daily treatments.
• the pharmaceutical compositions comprise dosage units containing the amount of the active ingredient to be administered once, or a few multiples or a half, third or fourth part thereof.
• dosage units are e.g. tablets, which can be powdered with grooves promoting the halving or quartering of the tablet in order to exactly administer the required amount of the active ingredient.
• compositions containing the active ingredient according to the present invention usually contain 0.01 to 500 mg of active ingredient in a single dosage unit. It is, of course possible that the amount of the active ingredient in some compositions exceeds the upper or lower limits defined above.
• compositions of the present invention may be formulated as different pharmaceutical dosage forms, such as but not limited to, solid oral dosage forms like tablets (e.g. buccal, sublingual, efferveseents, chewable, orodispersible, freeze dried), capsules, lozenges, pastilles, pills, orodispersible films, granules, powders; liquid oral dosage forms like solutions, emulsions, suspensions, syrups, elixires, oral drops; parenteral dosage forms like intravenous injections, intramuscular injections, subcutaneous injections; other dosage forms like eye drops, semi-solid eye preparations, transdermal dosage forms, suppositories, rectal capsules, rectal solutions, emulsions and suspensions, etc.
• solid oral dosage forms like tablets (e.g. buccal, sublingual, efferveseents, chewable, orodispersible, freeze dried), capsules, lozenges, pastilles, pills, orodispersible films, granules, powders
• the invention relates to pharmaceutical dosage forms specifically intended for pediatric use, such as but not limited to, solutions, syrups, elixirs, suspensions, powders for reconstitution as suspension, dispersible or effervescent tablets, chewable tablets, orally disintegrating tablets, tablets or coated tablets, sprinkle oral powder or granules, capsules.
• compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, emulsifying, suspending, entrapping, freeze-drying, extrusion, laminating, film-casting, granulating, grinding, encapsulating, dragee-making or tabietting processes.
• compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, earners, and excipients may ⁇ be used as suitable and as understood in the art.
• Suitable excipients for the preparation of the dosage forms may be selected from the following categories, such as but not limited to, tablet and capsule fillers, tablet and capsule binders, modified-release agents, disintegrants, glidants, lubricants, sweetening agents, taste- masking agents, flavoring agents, coating agents, surfactants, antioxidants, buffering agents, complexing agents, emulsifying agents, lyophilization aids, microencapsulating agents, ointment bases, penetration enhancers, solubilizing agents, solvents, suppository bases, suspending agents.
• tablet and capsule fillers tablet and capsule binders
• modified-release agents such as but not limited to, tablet and capsule fillers, tablet and capsule binders, modified-release agents, disintegrants, glidants, lubricants, sweetening agents, taste- masking agents, flavoring agents, coating agents, surfactants, antioxidants, buffering agents, complexing agents, emulsifying agents, lyophilization aids, microencapsulating agents
• the invention relates to the using of specific excipients which are able to improve the solubility, dissolution, penetration, adsorption or bioavailability of the active ingredient(s), such as but not limited to, hydrophilic polymers, hot melt extrusion excipients, surfactants, buffering agents, complexing agents, emulsifying agents, lyophilization aids, superdisintegrants, microencapsulating agents, penetration enhancers, solubilizing agents, co-solvents, suspending agents.
• specific excipients which are able to improve the solubility, dissolution, penetration, adsorption or bioavailability of the active ingredient(s), such as but not limited to, hydrophilic polymers, hot melt extrusion excipients, surfactants, buffering agents, complexing agents, emulsifying agents, lyophilization aids, superdisintegrants, microencapsulating agents, penetration enhancers, solubilizing agents, co-solvents, suspending agents.
• the compounds would be effective in the treatment of psychiatric, neurodevelopmental, neurological and other central nervous system disorders as well as peripheral conditions where stimulation of the GABAB receptor may offer therapeutic benefit.
• the assay was done in a buffer containing 50 mM Tris (pl l 7.4). 100 mM NaCl, 7 mM MgCl 2 , 1 mM EDTA and 1 mM DTT.
• Each assay tube contained 150 uL GDP (in a final concentration of 50 uM), 100 uL ligand and 125 ⁇ of the membrane suspension (250 _ug tissue/tube).
• the assay tubes were preincubated for 10 min at 30°C to assure equilibrium. Nonspecific binding was determined in the presence of 10 ⁇ GTPyS; basal binding was determined in the presence of buffer only.
• membranes were incubated for an additional 60 min at 30°C. The assay was terminated by rapid filtration through Packard UniFilter GF/B using a Packard harvester and washed four times with 1 mi ice-cold buffer.
• Rats were housed in groups of four in plastic cages with a wire grid top in a temperature and light-controlled laboratory animal care unit (22 ⁇ 2 °C, 12-h light/dark cycle, lights on at 6:00 AM) with ad libitum access to commercial pellet rat food and tap water. Investigations were approved by the Local Ethical Committee of Gedeon Richter Pic. and were carried out in strict compliance with the European Directive 2010/63/EU regarding the care and use of laboratory animals for experimental procedures and all efforts were made to minimize the number of animals as well as their suffering.
• the prenatal valproate model has excellent construct and face validity, therefore it is a widely accepted disease model of ASD (Christensen et al, JAMA 2013, 309, 1696-1703; Roullet et al, Neurotox. Teratol. 2013, 36, 45-56).
• ASD a widely accepted disease model of ASD
• time-mated female Wistar rats (Harlan UK) were administered a single dose of valproic acid (VP A, 600 mg/kg, i.p.) on gestational day 12.5.
• Male offspring were housed according to standard laboratory conditions until time of testing at postnatal day 59.
• test animal in this assay a test animal is allowed to investigate a eonspeeific separated by a dividing perforated wall or a similar area however, without a target eonspeeific.
• An autistic animal (such as a prenatally valproate-exposed rat) spends little time with social investigation during a test session.
• the inventors unexpectedly found that selected compounds of the invention in the oral dose range of 0.25 - 2 mg/kg were of great behavioral benefit in the present preclinical di sease model that recapitulates the core symptoms of ASD. The inventors therefore showed that these compounds may be of therapeutic potential for the treatment of core symptoms of ASD in humans.
• the compounds of Formula I can be prepared in accordance with the general knowledge of one skilled in the art and/or using methods set forth in the Example and/or Intermediate sections that follow. Solvents, temperatures, pressures, and other reaction conditions can readily be selected by one of ordinary skill in the art. Starting materials are commercially available and/or readily prepared by one skilled in the art.
• the title compound is prepared from 1-fert-butyl 3 -ethyl piperidine-l,3-dicarboxylate and 2-iodo propane according to the method described in Intermediate la.
• the title compound is prepared from 1-tert-butyl 3 -ethyl 3-(2-methylpropyl)piperidine-l,3- dicarboxylate according to the method described in Intermediate lb. Oil.
• the title compound is prepared from 1-tert-butyl 3 -ethyl 3-(2,2-difluoroethyl)piperidine- 1,3-dicarboxylate according to the method described in Intermediate lb. Oil.
• Examples 18 - 170 were prepared using analogues methods to those Examples described above and are exemplified below in Table 8.
• Active ingredient(s) 0,01 - 90% Filler 1 - 99.9% Binder 0 - 20% Disintegrant 0 - 20% Lubricant 0 - 10%
• Active ingredient(s) 0.01 - 50%
• Liquid vehicle 10 99,9%
• Active ingredient(s) 0.01 - 50%
• Active ingredient(s) 0.01 - 50%
• Active ingredient(s) 0.01 - 50%
• Active ingredient(s) 0.01 - 50%

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Psychiatry (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Obesity (AREA)
• Psychology (AREA)
• Addiction (AREA)
• Hematology (AREA)
• Physical Education & Sports Medicine (AREA)
• Diabetes (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=89992388

Family Applications (1)

Country Status (6)

Cited By (5)

Citations (1)

Family Cites Families (2)

• 2017
  • 2017-03-13 HU HU1700107A patent/HU231057B1/hu not_active IP Right Cessation
• 2018
  • 2018-03-12 US US16/493,018 patent/US10960007B2/en active Active
  • 2018-03-12 HU HUE18713015A patent/HUE056561T2/hu unknown
  • 2018-03-12 WO PCT/IB2018/051598 patent/WO2018167629A1/en not_active Ceased
  • 2018-03-12 JP JP2019549365A patent/JP7153661B2/ja active Active
  • 2018-03-12 EP EP18713015.8A patent/EP3596079B1/en active Active
  • 2018-03-13 AR ARP180100581A patent/AR111272A1/es unknown

Patent Citations (1)

Non-Patent Citations (36)

Also Published As

Similar Documents

Legal Events